MarketPeel
Insider Trading Intelligence
DS

David S. Snyder

COYA
CHIEF FINANCIAL OFFICER · COYA THERAPEUTICS, INC. · CIK 0001398625
FILING MIX · LIFETIME100%/0%
BUYS
10
SELLS
0
TOTAL VALUE
$38.5K
COMPANIES
2
ACTIVE SINCE
Mar 2020
HOLDINGS NOW
370,241
AVG SELL PX
TRADE KIND
SHOWING 10 / 10
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
4 backtested trades · 8 horizons · 1 pending
Forward-return performance of every backtestable P/S trade by David S. Snyder, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d4+50.00%-4.82%+0.53%-5.35%-3.66%
14d4+75.00%+1.01%+3.93%-2.92%-3.16%
30d4+25.00%+3.57%+8.38%-4.81%-17.66%
60d4+25.00%+20.42%+7.29%+13.13%-10.65%
90d4+25.00%+27.93%+12.00%+15.93%-13.10%
180d4+25.00%+1.30%+17.51%-16.21%-22.10%
1y4+75.00%+42.39%+31.43%+10.96%+23.20%
2y4(1 pending)+66.67%-13.11%+63.50%-76.61%-35.06%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
COYA · 140,041 shares · as of Jan 22, 2026
035,14170,281105,422140,562202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 10 buys / 0 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
COYA
COYA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
140,041140,041Jan 22, 2026Jan 26, 2026View →
COYA
COYA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
140,562140,562Jan 9, 2025Jan 13, 2025View →
COYA
COYA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
1,800$7.19$12.9K8,800Nov 14, 2024Nov 14, 2024View →
COYA
COYA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
70,59670,596Jun 3, 2024Jun 5, 2024View →
COYA
COYA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
81,81981,819Jan 31, 2024Feb 2, 2024View →
COYA
COYA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
115,000115,000Feb 27, 2023Mar 1, 2023View →
COYA
COYA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
7,0007,000Jan 3, 2023Jan 4, 2023View →
COYA
COYA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
3,5003,500Jan 3, 2023Jan 4, 2023View →
XCUR
EXICURE, INC.
PURCHASEGRANT
Stock grant
230,200230,200Mar 13, 2020Mar 16, 2020View →
XCUR
EXICURE, INC.
PURCHASE
Chief Financial Officer
18,248$1.40$25.6K18,248Mar 12, 2020Mar 16, 2020View →
Other insiders · COYA
Loading peer insiders…
About this filer
CIK 0001398625
ROLE
Chief Financial Officer
PRIMARY
COYA
COMPANIES
2
ACTIVE SINCE
Mar 2020
MARKETPEEL · /INSIDER/0001398625DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback